Intuitive Surgical Shares Face Pressure Amid Growth Concerns

Despite posting impressive fourth-quarter 2025 results, Intuitive Surgical’s forward-looking guidance has unsettled investors. The stock has retreated significantly from recent highs, even as the company reported double-digit revenue growth and exceeded profit expectations. The market is now questioning whether the pioneer in robotic-assisted surgery is entering a period of sustained deceleration or if this is merely a healthy correction following a record run.

Operational Strength and Recurring Revenue Model

The company’s latest operational figures demonstrate its continued fundamental health. Intuitive Surgical delivered strong performance across several key metrics in Q4 2025:

• Revenue Growth: Sales climbed 19% year-over-year to $2.9 billion.
• Installed Base: The global number of da Vinci systems in use grew to over 11,000.
• Innovation: The new “da Vinci 5” system received regulatory clearance for cardiac surgery procedures in late January 2026.

This technological leadership is further reinforced by a resilient business model. Approximately 81% of total revenue stems from recurring sources, such as instruments, accessories, and services, providing significant stability and predictability in volatile market conditions.

Conservative Outlook Triggers Market Reassessment

The primary catalyst for the recent investor skepticism is the company’s forecast for the 2026 fiscal year. Management now anticipates procedure growth for its da Vinci systems to be in the range of 13% to 15%. This represents a notable slowdown from the 18% growth achieved in the previous year. The announcement of this deceleration has prompted a broad reassessment of valuation expectations among shareholders.

Should investors sell immediately? Or is it worth buying Intuitive Surgical?

Consequently, the stock has faced selling pressure. Shares currently trade at $478.49, marking a decline of roughly 19% from the 52-week high of $592.85. The price now sits below its 50-day moving average, reflecting the shift in market sentiment.

Institutional and Analyst Confidence Endures

While short-term traders have reacted nervously, confidence from professional investors and analysts remains largely intact. Firms like Piper Sandler have recently reaffirmed their buy ratings, with price targets as high as $620. They cite the company’s formidable competitive moat and the long-term potential of its new device generation.

Institutional interest also persists. Recent SEC filings reveal that major holders, including ABN AMRO Bank, have increased their positions. Overall, institutional investors control approximately 83.6% of the company’s shares. Although competitors like Medtronic with its Hugo system are entering the market, Intuitive Surgical’s substantial lead, bolstered by its established ecosystem and surgeon training programs, is considered significant.

Market participants are now focused on the broader rollout of the da Vinci 5 system. With the current share price hovering just above the 200-day moving average of $473.26, the technical reaction at this key level is likely to be crucial for determining the stock’s near-term trajectory this spring.